| Overview |
| bs-0875R |
| PKN2 Polyclonal Antibody |
| IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PKN2 |
| 881-984/984 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 5586 |
| Nucleus |
| protein kinase N2; Serine/threonine-protein kinase N2; Protein kinase C-like 2; Protease-activated kinase 2; PAK-2; Cardiolipin activated protein kinase Pak2; MGC150606; MGC71074; PAK2; PRK2; PRKCL2; PRO2042; Protein kinase C like 2; Protein kinase C related kinase 2. |
| Protein-kinase-C-related kinases (PRKs) are part of the lipid-regulated protein kinases (PKC) which also include liver PAK & PKN. Human PRK1 and PRK2 share structurally similar catalytic domains, but less similar N-terminal regulatory regions suggesting different regulatory domain functions. PRK1 and PRK2, as well as a third member of this family, PRK3, show distinct patterns of expression in adult tissues. Additionally, the serine-threonine kinase PRK2 can be specifically cleaved by caspase-3 (and/or caspase-3-like subfamily members) during apoptosis |
| Application Dilution |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz